A randomized trial of iloprost in patients with intermittent claudication

Vascular Medicine

Volumn 13, Issue 1, 2008, Pages 5-13

  Creager, Mark A ^a   Pande, Reena L ^a   Hiatt, William R ^b   Halperin, Jonathan ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Iloprost; Intermittent claudication; Pentoxifylline; Peripheral arterial disease; Randomized controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ILOPROST; PENTOXIFYLLINE; PLACEBO;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG OVERDOSE; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE TEST; FEMALE; HEADACHE; HEART FAILURE; HEART INFARCTION; HOT FLUSH; HUMAN; INTERMITTENT CLAUDICATION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; TREADMILL EXERCISE; TREATMENT DURATION; VASODILATATION;

ADMINISTRATION, ORAL; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ILOPROST; INTERMITTENT CLAUDICATION; MALE; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECOVERY OF FUNCTION; TREATMENT FAILURE; UNITED STATES; VASODILATOR AGENTS; WALKING;

EID: 42649129319     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X07084910     Document Type: Article

References (38)

1. Selvin, E, Erlinger, TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-743.
2. Norgren, L, Hiatt, WR, Dormandy, JA, Nehler, MR, Harris, KA, Fowkes, FG. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45(1 suppl): S5-S67.
3. Kannel, WB, McGee, DL. Update on some epidemiologic features of intermittent claudication: the Framingham Study. J Am Geriatr Soc 1985; 33: 13-18.
4. Hiatt, WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.
5. McDermott, MM, Greenland, P, Liu, K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286: 1599-1606.
6. Porter, JM, Cutler, BS, Lee, BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.
7. Thompson, PD, Zimet, R, Forbes, WP, Zhang, P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-1319.
8. Grant, SM, Goa, KL. Iloprost. A review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992; 43: 889-924.
9. Ciuffetti, G, Sokola, E, Lombardini, R, Pasqualini, L, Pirro, M, Mannarino, E. The influence of iloprost on blood rheology and tissue perfusion in patients with intermittent claudication. Kardiol Pol 2003; 59: 197-204.
10. Dormandy, JA. Prostanoid drug therapy for peripheral arterial occlusive disease - the European experience. Vasc Med 1996; 1: 155-158.
11. ICAI Study Group. Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999; 130: 412-421.
12. UK Severe Limb Ischaemia Study Group. Treatment of limb threatening ischaemia with intravenous iloprost: a randomised double-blind placebo controlled study. Eur J Vasc Surg 1991; 5: 511-516.
13. Brass, EP, Anthony, R, Dormandy, J, et al. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter 6-month outcomes in patients with critical leg ischemia. J Vasc Surg 2006; 43: 752-759.
14. Diehm, C, Balzer, K, Bisler, H, et al. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. J Vasc Surg 1997; 25: 537-544.
15. Brevetti, G, Rossini, A, Perna, S, et al. Beneficial effect of a new prostacyclin derivative on the walking capacity in patients with peripheral arterial insufficiency. Angiology 1989; 40: 907-913.
16. Belch, JJ, Bell, PR, Creissen, D, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95: 2298-2302.
17. Mangiafico, RA, Messina, R, Attina, T, Dell'Arte, S, Giuliano, L, Malatino, LS. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication. Angiology 2000; 51: 441-449.
18. Boger, RH, Bode-Boger, SM, Thiele, W, Creutzig, A, Alexander, K, Frolich, JC. Restoring vascular nitric oxide formation by 1-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-1344.
19. Milio, G, Coppola, G, Novo, S. The effects of prostaglandin E-1 in patients with intermittent claudication. Cardiovasc Hematol Disord Drug Targets 2006; 6: 71-76.
20. Amendt, K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 2005; 56: 409-415.
21. Hashiguchi, M, Ohno, K, Saito, R. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication. Yakugaku Zasshi 2004; 124: 321-332.
22. Reiter, M, Bucek, RA, Stumpflen, A, Minar, E. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2004(1:): CD000986.
23. Reiter, M, Bucek, RA, Stumpflen, A, Dirisamer, A, Minar, E. Prostanoids in the treatment of intermittent claudication - a meta-analysis. VASA 2002; 31: 219-224.
24. Lievre, M, Morand, S, Besse, B, Fiessinger, JN, Boissel, JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102: 426-431.
25. Mohler, ER, Hiatt, WR, Olin, JW, Wade, M, Jeffs, R, Hirsch, AT. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41: 1679-1686.
26. Gardner, AW, Skinner, JS, Cantwell, BW, Smith, LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 1991; 23: 402-408.
27. Regensteiner, JG, Steiner, JF, Panzer, RJ, Hiatt, WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol 1990; 2: 142-152.
28. McDermott, MM, Liu, K, Guralnik, JM, Martin, GJ, Criqui, MH, Greenland, P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg 1998; 28: 1072-1081.
29. McHorney, CA, Ware, JE, Lu, JF, Sherbourne, CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994; 32: 40-66.
30. McHorney, CA, Ware, JE, Raczek, AE. The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-263.
31. Ware, JE, Sherbourne, CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473-483.
32. Moncada, S, Vane, JR. The role of prostacyclin in vascular tissue. Fed Proc 1979; 38: 66-71.
33. Dawson, DL, Zheng, Q, Worthy, SA, Charles, B, Bradley, DV. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. Angiology 2002; 53: 509-520.
34. Rao, KM, Simel, DL, Cohen, HJ, Crawford, J, Currie, MS. Effects of pentoxifylline administration on blood viscosity and leukocyte cytoskeletal function in patients with intermittent claudication. J Lab Clin Med 1990; 115: 738-744.
35. Schratzberger, P, Dunzendorfer, S, Reinisch, N, et al. Mediator-dependent effects of pentoxifylline on endothelium for transmigration of neutrophils. Immunopharmacology 1999; 41: 65-75.
36. Lindgarde, F, Jelnes, R, Bjorkman, H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989; 80: 1549-1556.
37. Lindgarde, F, Labs, KH, Rossner, M. The pentoxifylline experience: exercise testing reconsidered. Vasc Med 1996; 1: 145-154.
38. Dawson, DL, Cutler, BS, Hiatt, WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109: 523-530.